← All trials
NCT03540420
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2018
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2026
- First posted
- —
- Last posted
- —
- Enrollment
- 212
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Norwegian University of Science and TechnologyLead sponsor
- Vestre Viken Ringerike SykehusCollaborator
- Norwegian University of Science and TechnologyStudy director
- University of StavangerCollaborator
- University Hospital of North NorwayCollaborator
- The Hospital of VestfoldCollaborator
- Oslo Metropolitan UniversityCollaborator
- Sorlandet Hospital HFCollaborator
- University of BergenCollaborator
- Helse Møre og Romsdal HFCollaborator
- Levanger HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.